Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma Meeting Abstract
| Authors: | McKean, M.; Aggen, D. H.; Lakhani, N. J.; Bashir, B.; Luke, J. J.; Hoffman-Censits, J. H.; Alhalabi, O.; Bowman, I. A.; Guancial, E. A.; Tan, A.; Lingaraj, T.; Timothy, M.; Kacena, K.; Malek, K. S.; Santillana, S. |
| Abstract Title: | Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680304885 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS3169 |
| Notes: | Meeting Abstract: TPS3169 -- Meeting also held virtually -- Source: Wos |
